US FDA approves Merck’s therapy for rare lung condition By Reuters
[ad_1] By Leroy Leo and Michael Erman (Reuters) -The U.S. Food and Drug Administration on Tuesday approved Merck’s treatment for adults with high blood pressure...
Citi starts ArriVent stock with buy rating citing promising lung cancer drug By Investing.com
[ad_1] © Reuters. Tuesday, Citi initiated coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and a price target of $30.00. The firm’s analyst highlighted...
Puma Biotech starts phase II trial for lung cancer therapy By Investing.com
[ad_1] © Reuters. LOS ANGELES – Puma Biotechnology, Inc. (NASDAQ: NASDAQ:) has commenced a Phase II clinical trial to evaluate the efficacy of its drug...